Imperforate hymen with elevated serum CA 125 and CA 19-9 levels

Area of Science:

• Gynecology
• Reproductive Medicine
• Surgical Oncology

Background:

• Imperforate hymen is a congenital condition that can lead to significant clinical symptoms.
• Elevated levels of cancer antigen 125 (CA 125) and cancer antigen 19-9 (CA 19-9) have been observed in patients with imperforate hymen.
• These elevated tumor markers can be misconstrued as indicators of gynecologic malignancy, delaying appropriate diagnosis and treatment.

Purpose of the Study:

• To characterize the clinical presentation of imperforate hymen.
• To investigate the association between imperforate hymen and serum levels of CA 125 and CA 19-9.
• To highlight the importance of accurate diagnosis in differentiating imperforate hymen from other gynecologic conditions.

Main Methods:

• Retrospective analysis of 14 patients diagnosed with imperforate hymen.
• Evaluation of clinical characteristics, symptoms, and surgical management.
• Measurement of serum CA 125 and CA 19-9 levels pre- and post-operatively.

Main Results:

• All 14 patients presented with primary amenorrhea and pelvic pain.
• Common symptoms included cryptomenorrhea, pelvic pain, palpable abdominal mass, and voiding difficulties.
• Preoperative CA 125 and CA 19-9 levels were significantly elevated compared to postoperative levels (p < 0.001).

Conclusions:

• Imperforate hymen is a benign condition that can lead to elevated serum CA 125 and CA 19-9 levels.
• Accurate diagnosis of imperforate hymen is essential to avoid misdiagnosis of gynecologic malignancy.
• Tumor markers are not diagnostic for imperforate hymen and should be interpreted cautiously in the presence of pelvic mass.